Edwards Lifesciences (EW) executive Lippis sold 620 shares for $50.3K at $81.14 under a 10b5-1 plan
Insider transactions reported
Daniel J. Lippis (Cvp, Tavr at Edwards Lifesciences Corporation, EW) reported that they sold 620 shares for $50.3K at $81.14, and acquired 620 shares at $72.68 on May 18, 2026. After these transactions the filing shows 40,410.91 shares held directly.
- Reporting person
- Lippis Daniel J.
- Role
- CVP, TAVR
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| May 18, 2026 | Exercise or conversion of a derivative (M) | Common Stock1 | +620 | $72.68 | $45.1K | 41,030.9103 direct |
| May 18, 2026 | Open-market sale (S) | Common Stock1 | -620 | $81.14 | $50.3K | 40,410.9103 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| May 18, 2026 | Exercise or conversion of a derivative (M) | Employee Stock Option (Right to Acquire)On 620 Common Stock | -620 | - | - | 6,190 direct |
Holdings before and after
- Employee Stock Option (Right to Acquire): 6,810 to 6,190 direct
Footnotes from the filing
- 1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
FAQ
What did Lippis report in this EW Form 4?
Daniel J. Lippis (Cvp, Tavr at Edwards Lifesciences Corporation, EW) reported that they sold 620 shares for $50.3K at $81.14, and acquired 620 shares at $72.68 on May 18, 2026. After these transactions the filing shows 40,410.91 shares held directly.
How many EW shares does Lippis hold after this filing?
The filing shows 40,410.91 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this EW insider sale made under a 10b5-1 plan?
The filing's footnotes mention a Rule 10b5-1 trading plan. Such a plan sets the terms of future trades in advance.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Historical context for EW
Across the 23 sessions after earlier EW headlines, the stock closed higher 12 times and lower 11 times, with a median move of 0.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | EW | SPY |
|---|---|---|---|
| May 5, 2026 | Edwards Lifesciences Announces Appointment of CFO | -0.5% | +0.8% |
| May 4, 2026 | Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences' Resilia Tissue | -0.8% | -0.4% |
| Apr 28, 2026 | Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference | -1.4% | -0.5% |
| Apr 24, 2026 | Edwards Lifesciences Reports First Quarter Results | +5.6% | +0.8% |
| Apr 16, 2026 | Edwards Lifesciences to Host Earnings Conference Call on April 23, 2026 | +1.1% | +0.2% |
| Apr 1, 2026 | Edwards Lifesciences upgraded by Wolfe Research with a new price target | +1.5% | +0.8% |
Earlier insider filings at EW
- May 18, 2026CVP,Strategy/Corp Development Bobo Donald E Jr sold $1,472,678 worth of shares (17,968 units at $81.96), decreasing direct ownership by 30% to 22,798 units (SEC Form 4)
- May 12, 2026CEO Zovighian Bernard J converted options into 47,207 shares, covered exercise/tax liability with 26,198 shares, gifted 26,640 shares, received a gift of 26,640 shares and sold $2,833,013 worth of shares (36,351 units at $77.93) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 99,165 units (SEC Form 4)
- May 12, 2026CVP,Strategy/Corp Development Bobo Donald E Jr converted options into 13,457 shares and covered exercise/tax liability with 7,469 shares, increasing direct ownership by 22% to 32,766 units (SEC Form 4)
- May 12, 2026CVP, TMTT & Surgical Chopra Daveen converted options into 13,583 shares and covered exercise/tax liability with 7,538 shares, increasing direct ownership by 15% to 45,824 units (SEC Form 4)
- May 12, 2026CVP, Chief Financial Officer Ullem Scott B. covered exercise/tax liability with 11,004 shares and converted options into 19,830 shares, increasing direct ownership by 23% to 46,740 units (SEC Form 4)
Keep researching EW
- EW insider tradesEvery buy and sale reported by Edwards Lifesciences Corporation officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- EW earnings historyPast Edwards Lifesciences Corporation earnings releases, newest first.
- EW financial statementsRevenue, profit, cash flow and balance sheet from Edwards Lifesciences Corporation's SEC filings.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Industrial Specialties
Follow EW and get a push notification the moment its next story breaks.